- Home
- SJT vs CRBP Comparison
SJT vs CRBP Comparison
Compare SJT & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SJT
- CRBP
- Stock Information
- Founded
- SJT 1980
- CRBP 2009
- Country
- SJT United States
- CRBP United States
- Employees
- SJT N/A
- CRBP 19
- Industry
- SJT Oil & Gas Production
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- SJT Energy
- CRBP Health Care
- Exchange
- SJT Nasdaq
- CRBP Nasdaq
- Market Cap
- SJT 181.8M
- CRBP 158.3M
- IPO Year
- SJT N/A
- CRBP N/A
- Fundamental
- Price
- SJT $3.91
- CRBP $13.00
- Analyst Decision
- SJT
- CRBP Strong Buy
- Analyst Count
- SJT 0
- CRBP 8
- Target Price
- SJT N/A
- CRBP $62.00
- AVG Volume (30 Days)
- SJT 241.1K
- CRBP 313.3K
- Earning Date
- SJT 12-27-2024
- CRBP 11-07-2024
- Dividend Yield
- SJT 3.17%
- CRBP N/A
- EPS Growth
- SJT N/A
- CRBP N/A
- EPS
- SJT 0.19
- CRBP N/A
- Revenue
- SJT $11,031,594.00
- CRBP N/A
- Revenue This Year
- SJT N/A
- CRBP N/A
- Revenue Next Year
- SJT N/A
- CRBP N/A
- P/E Ratio
- SJT $20.57
- CRBP N/A
- Revenue Growth
- SJT N/A
- CRBP N/A
- 52 Week Low
- SJT $3.21
- CRBP $5.25
- 52 Week High
- SJT $5.81
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- SJT 45.65
- CRBP 25.10
- Support Level
- SJT $3.78
- CRBP $12.90
- Resistance Level
- SJT $4.31
- CRBP $16.21
- Average True Range (ATR)
- SJT 0.16
- CRBP 0.95
- MACD
- SJT -0.04
- CRBP -0.16
- Stochastic Oscillator
- SJT 28.33
- CRBP 1.69
About SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.